Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on De protection. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
High-purity Remdesivir intermediate preparation via BCl3 deprotection. Reduces impurities, ensures supply chain stability for API manufacturing and cost reduction.
Novel patent CN104530112A offers high-yield Everolimus intermediate synthesis. Reduces costs and improves supply chain reliability for immunosuppressor manufacturing.
Novel one-pot method for etoposide intermediate. Reduces cost, improves safety, ensures high purity for pharmaceutical supply chains.
Patent CN104662008A reveals novel tetrazole deprotection for Angiotensin II receptor blockers. Achieve cost reduction and supply chain reliability in pharmaceutical intermediates manufacturing.
Patent CN105601604B enables cost reduction in pharmaceutical intermediate manufacturing through green synthesis with high selectivity and scalable production.
Discover how this metal-free synthesis of 3-ethynyl imidazo[1,2-b]pyridazine reduces 8-step routes to 2 steps, cutting costs and eliminating metal residues for BCR-ABL kinase inhibitor manufacturing.
Solve low yield and impurity issues in camptothecin synthesis. New deprotection method cuts solvent use, boosts purity to 99.9% and recovers mother liquor for cost savings.
Solve NMR imaging agent supply chain risks with this patent-validated synthesis. 92-96% yields, no toxic reagents, and 75%+ step recovery. Scale to 100MT/yr.